Genetic signatures on radical prostatectomy specimens: clinical implications

Prostate cancer is the most common non-dermatologic cancer in the United States, with an estimated 3.3 million men in the United States living with the disease in 2016. In 2017, an estimated 161,000 new cases and 26,000 deaths are expected (1,2). The majority of incident cases diagnosed are organ-confined. While active surveillance is often an appropriate management strategy, many patients with newly diagnosed prostate cancer undergo some form local treatment with curative intent. Radical prostatectomy remains the most common treatment modality for men under 65 years of age, though decreases with age (1).